接受嵌合抗原受体T细胞治疗的血液系统恶性肿瘤患者的造血恢复情况
该研究分析了83例接受CAR-T细胞治疗的血液系统恶性肿瘤患者,描述了造血恢复模式并评估相关因素。输注后1个月血红蛋白、血小板、中性粒细胞和白细胞恢复率分别为61%、51%、33%和28%,3个月分别为93%、90%、80%和59%。多变量分析显示,≥3级细胞因子释放综合征或免疫效应细胞相关神经毒性综合征与1个月时未完全恢复显著相关。
要点
- 输注后1个月血红蛋白、血小板、中性粒细胞和白细胞恢复率分别为61%、51%、33%和28%。
- 输注后3个月上述四项恢复率分别为93%、90%、80%和59%。
- ≥3级CRS或ICANS与1个月时未完全恢复显著相关。
核心结论
- CAR-T治疗后1个月和3个月造血恢复率逐渐提高,但部分患者恢复延迟。
- ≥3级CRS或ICANS与1个月时未完全恢复显著相关,尚需更大规模前瞻性研究进一步验证。
研究设计与样本
- 分析83例接受CAR-T细胞治疗的血液系统恶性肿瘤患者,包括axicabtagene ciloleucel(n=30)或tisagenlecleucel(n=10)治疗B细胞淋巴瘤、CD19-28z CAR-T治疗B细胞急性淋巴细胞白血病(NCT01044069;n=37)、靶向B细胞成熟抗原的CAR-T治疗多发性骨髓瘤(NCT03070327;n=6)。
主要发现
- 输注后1个月血红蛋白、血小板、中性粒细胞和白细胞恢复率分别为61%、51%、33%和28%。
- 输注后3个月上述四项恢复率分别为93%、90%、80%和59%。
- 单变量分析显示,ICANS分级升高、基线血细胞减少、CAR构建体、较高的峰值C反应蛋白或铁蛋白水平与1个月时完全计数恢复可能性降低显著相关;CRS呈现类似趋势。
- 调整基线血细胞减少和CAR构建体后,≥3级CRS或ICANS仍与1个月时无完全计数恢复显著相关。
- 1个月时未完全计数恢复的患者中观察到较高水平的血管内皮生长因子和巨噬细胞衍生趋化因子,但无统计学显著性。
局限性
- 原文指出尚需在更大规模的前瞻性研究中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Factors contributing to hematopoietic recovery following chimeric antigen receptor (CAR) T-cell therapy have not been well studied. In an analysis of 83 patients with hematologic malignancies treated with CAR T-cell therapy, we describe patterns of hematopoietic recovery and evaluate potentially associated factors. We included patients who received axicabtagene ciloleucel (n = 30) or tisagenlecleucel (n = 10) for B-cell lymphoma, CD19-28z CAR T therapy for B-cell acute lymphoblastic leukemia (NCT01044069; n = 37), or B-cell maturation antigen targeting CAR T cells for multiple myeloma (NCT03070327; n = 6). Patients treated with CAR T cells who had not progressed, died, or received additional chemotherapy had "recovered" (per definition in Materials and methods section) hemoglobin, platelet, neutrophil, and white blood cell counts at rates of 61%, 51%, 33%, and 28% at month 1 postinfusion and 93%, 90%, 80%, and 59% at month 3 postinfusion, respectively. Univariate analysis showed that increasing grade of immune effector cell-associated neurological syndrome (ICANS), baseline cytopenias, CAR construct, and higher peak C-reactive protein or ferritin levels were statistically significantly associated with a lower likelihood of complete count recovery at 1 month; a similar trend was seen for cytokine release syndrome (CRS). After adjustment for baseline cytopenia and CAR construct, grade ≥3 CRS or ICANS remained significantly associated with the absence of complete count recovery at 1 month. Higher levels of vascular endothelial growth factor and macrophage-derived chemokines, although not statistically significant, were seen patients without complete count recovery at 1 month. This remains to be studied further in larger prospective studies.
引用
- Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020. PMID: 32780846. doi:10.1182/bloodadvances.2020002509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。